Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reneo Pharmaceuticals (RPHM)
NASDAQ:RPHM
RESEARCH TOOLSreports
Reneo Pharmaceuticals (RPHM) Stock Price & Analysis
222 Followers
RPHM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.98 - $11.30
Previous Close$1.76
Volume76.42K
Average Volume (3M)223.04K
Market Cap
$58.82M
Enterprise Value-$65.66M
Total Cash (Recent Filing)$125.61M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)-0.7
Beta0.54
Next Earnings
May 08, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding33,420,808
10 Day Avg. Volume100,646
30 Day Avg. Volume223,043
Standard Deviation0.32
R-Squared0.00152
Alpha-0.00962
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.30
Forecast
1Y Price Target
$1.10Price Target Upside-37.50% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
Reneo Pharmaceuticals News
PremiumCompany Announcements
Reneo Pharmaceuticals Announces Workforce Reduction Costs
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressMavodelpar, an oral PPARδ agonist, has shown promising results, suggesting a high potential for successful outcomes in the STRIDE study.
Financial StabilityCurrent cash reserves exceed $100M, providing RPHM with a solid foundation to explore future opportunities and strategies.
Patient RecruitmentRPHM has achieved strong patient recruitment by enrolling 88% of participants in the STRIDE-AHEAD OLE study, reflecting the company's efficiency and the treatment's appeal to patients.
Bears Say
Clinical Trial FailurePivotal trial failure eliminates hope for future mavodelpar development; downgrading to Neutral.
Financial UncertaintyReneo faces considerable uncertainty moving forward with suspended development of mavodelpar and no clear path forward for the company.
Operational DownsizingThe company will suspend mavodelpar development and implement cost-saving initiatives, which includes a workforce reduction of approximately 70%.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RPHM FAQ
What was Reneo Pharmaceuticals’s price range in the past 12 months?
Reneo Pharmaceuticals lowest stock price was $0.98 and its highest was $11.29 in the past 12 months.
What is Reneo Pharmaceuticals’s market cap?
Currently, no data Available
When is Reneo Pharmaceuticals’s upcoming earnings report date?
Reneo Pharmaceuticals’s upcoming earnings report date is May 08, 2024 which is in 13 days.
How were Reneo Pharmaceuticals’s earnings last quarter?
Reneo Pharmaceuticals released its earnings results on Mar 28, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.578 by -$0.122.
Is Reneo Pharmaceuticals overvalued?
According to Wall Street analysts Reneo Pharmaceuticals’s price is currently Overvalued.
Does Reneo Pharmaceuticals pay dividends?
Reneo Pharmaceuticals does not currently pay dividends.
What is Reneo Pharmaceuticals’s EPS estimate?
Reneo Pharmaceuticals’s EPS estimate is -$0.44.
How many shares outstanding does Reneo Pharmaceuticals have?
Reneo Pharmaceuticals has 33,420,807 shares outstanding.
What happened to Reneo Pharmaceuticals’s price movement after its last earnings report?
Reneo Pharmaceuticals reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.578. Following the earnings report the stock price went up 0.606%.
Which hedge fund is a major shareholder of Reneo Pharmaceuticals?
Among the largest hedge funds holding Reneo Pharmaceuticals’s share is Highbridge Capital Management LLC. It holds Reneo Pharmaceuticals’s shares valued at 2M.
---
Reneo Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.10 (-37.50% Downside)
$1.10 (-37.50% Downside)
Blogger Sentiment
Bullish
RPHM Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 671.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 11.3%
Last 30 Days ▼ 11.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.04%
12-Months-Change
Fundamentals
Return on Equity
-82.07%
Trailing 12-Months
Asset Growth
-0.69%
Trailing 12-Months
Company Description
Reneo Pharmaceuticals
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
---
RPHM Stock 12 Months Forecast
Average Price Target
$1.10
▼(-37.50% Downside)
Technical Analysis
RegenXBio
―
Rocket Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Repare Therapeutics
―
Best Analysts Covering RPHM
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-50.30%
reiterated a sell rating 28 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -50.30% per trade.
---